Genome-wide association studies have identified 196 high confidence independent signals associated with breast cancer susceptibility. Variants within these signals frequently fall in distal regulatory DNA elements that control gene expression. We designed a Capture Hi-C array to enrich for chromatin interactions between the credible causal variants and target genes in six human mammary epithelial and breast cancer cell lines. We show that interacting regions are enriched for open chromatin, histone marks for active enhancers and transcription factors relevant to breast biology. We exploit this comprehensive resource to identify candidate target genes at 139 independent breast cancer risk signals, and explore the functional mechanism underlying altered risk at the 12q24 risk region. Our results demonstrate the power of combining genetics, computational genomics and molecular studies to rationalize the identification of key variants and candidate target genes at breast cancer GWAS signals.
INTRODUCTION
Breast cancer is known to have an important inherited component. While rare coding mutations in susceptibility genes such as BRCA1, BRCA2 and PALB2 confer a high risk of breast cancer, these account for less than one quarter of the familial risk 1 . Much of the remaining heritability is due to the combination of a large number of common, low-penetrance variants 2, 3 . Genome-wide association studies (GWAS) have been a powerful tool to identify disease-associated genetic variants, but these studies do not directly address the underlying biological mechanisms. A combination of fine scalemapping, bioinformatic and functional studies are required to establish this link 4 
. The Breast Cancer
Association Consortium (BCAC) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have recently performed large-scale genetic fine-mapping of 150 breast cancer susceptibility regions in ~217,000 breast cancer cases and controls of European ancestry 5 .
Stepwise multinomial logistic regression analysis identified 196 high confidence independent risk signals, defined as having association p values < 10 -6 after adjusting for other variants. Fachal et al (2018) used these data to define sets of credible causal variants (CCVs) for each signal, defined as variants with p values within two orders of magnitude of the top variant.
Here, we applied Variant Capture Hi-C (VCHi-C) and PCHi-C to normal breast and breast cancer cell lines to generate a catalog of interactomes. We report several hundred candidate target genes in breast cancer risk regions including some known cancer driver genes but also many molecular targets not previously implicated in breast cancer etiology.
RESULTS

VCHi-C and PCHi-C interaction profiling
To enrich for chromatin interactions relevant to breast cancer risk, we designed two capture arrays, Variant Capture (VC) and Promoter Capture (PC). The VCHi-C baits were designed to HindIII fragments that contained at least one CCV, regardless of the CCV regulatory potential (Figure 1A ; 5 ).
We could design baits to 190/196 signals (97%) which included 6044/7394 CCVs. The PCHi-C baits were designed to annotated promoters within 1 Mb of CCVs at breast cancer risk signals ( Figure   1A ). This dual-capture approach ensured comprehensive coverage of each risk signal and provided independent validation of interactions. We performed in situ VCHi-C and PCHi-C 16, 18 in two nontumorigenic breast cell lines (B80T5, MCF10A), two estrogen receptor positive (ER+; MCF7, T47D) and two ER-(MDAMB231, Hs578T) breast cancer cell lines. Sequencing of both captures produced over one billion unique di-tags involving CCV-containing fragments and annotated promoters (Table   S1 ). To assess the robustness of the approach, each CHi-C experiment was conducted in two biological replicates per cell type. We observed strong correlation between the replicates, particularly when captured interaction pairs were within 0.5 Mb (Figure S1A) .
We initially used the CHiCAGO pipeline 23 to assign confidence scores to interactions derived from the VCHi-C and PCHi-C (Table S2) . Principal component analysis (PCA) based on CHiCAGO scores demonstrated concordance for individual replicates in the VCHi-C and PCHi-C. PCA was able to separate ER+ breast cancer from normal breast or ER-breast cancer cell lines (Figure 1B) .
Using a strict interaction threshold (CHiCAGO score ³5, intrachromosomal and interaction distance £2Mb) we detected on average ~10,000 VCHi-C and ~27,000 PCHi-C high-confidence interactions per cell type ( Figure 1C and Table S2 ). The difference in interaction number between captures likely reflects the higher number of PCHi-C baits. In addition, VCHi-C baits were designed to all possible CCV-containing HindIII fragments, but some CCVs will be correlated passenger variants or function through alternative non-looping mechanisms, such as promoter variants. For the VCHi-C, we detected a median of five variant-interacting regions (VIRs; Figure 1A ) per bait per cell type, of which 3-5% interacted with an annotated protein-or non-coding promoter. Similarly, for the PCHi-C, we detected a median of five promoter-interacting regions (PIRs; Figure 1A ) per bait per cell type, where 2.4% specifically interacted with a CCV-containing fragment (Figure S1B and Table S2 ). The median linear distance between interactions from either capture ranged from 192-405 kb ( Figure   S1C ) and ~70% of the CHi-C interactions occurred within TAD boundaries. Hierarchical clustering based on CHiCAGO scores separated the cells lines based on ER-status ( Figure 1D) , which suggested that ER status mediates cell-type specificity of the interactomes. We also observed a positive correlation (Pearson's r = 0.60-0.84) in CHiCAGO scores for interactions detected in both the VCHi-C and PCHi-C (Figure S1D) , thus validating our approach.
Interacting regions are enriched for regulatory features, eQTLs and CCVs in breast cells
We first annotated CHiCAGO-scored PIRs in each breast cell type with DNase-seq data derived from a diverse panel of cells and tissues as part of the Roadmap Epigenomics Project 24 . We found PIRs to be enriched for regions of accessible chromatin in human mammary epithelial cells (HMEC), as compared to non-breast cells (Figures 2A and S2A) . To explore this observation in additional breast cells, we annotated PIRs with assay for transposase-accessible chromatin sequencing (ATAC-seq) peaks in five breast cell lines ( Table S3 ) and noted that the enrichment signals were strongest from PIRs detected in the matched cell line (Figure 2B) . We next investigated the epigenetic makeup of PIRs using ChIP-seq data for histone modifications and other DNA-binding proteins in human cell lines. PIRs were significantly enriched for histone marks associated with active enhancers (H3K27ac and H3K4me1) as compared to inactive elements which are typically marked by the polycomb-associated mark H3K27me3 (Figure 2C) .
Binding sites for several structural proteins with established roles in chromatin looping were also enriched in PIRs, including CTCF and the cohesin subunits RAD21 and STAG1 (Figure 2D) , consistent with the role of these factors in mediating long-range genomic interactions 9, 12 .
Associations were also observed for the cistromes of important breast cancer transcription factors (TFs); ESR1, FOXA1 and GATA3 (Figure 2D) . This enrichment was stronger in the ER+ MCF7 (z-score=5.04) and T47D (z-score=2.97) cell lines as compared to available ER-breast cancer, normal breast and other non-breast cell lines (Figure S2B) , consistent with an additional layer of ER-mediated cell-type specificity 25 . Applying the same enrichment criteria, we also found VIRs to be enriched in ATAC-seq peaks in the matched cell associated with active enhancers (H3K27ac and H3K4me1) and also for H3K4me3, which marks active gene promoters (Figure 2F) , supporting the notion that promoters and enhancers cooperatively communicate through transcriptionally active chromatin 26 .
To demonstrate PIR and VIR gene regulatory function, we assessed the overlap of expression quantitative trait loci (eQTLs) in normal breast tissue from the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort 2, 27 . We found 800 eQTL genes (eGenes) with eSNPs (false discovery rate (FDR)<0.05) within PIRs in at least one analyzed breast cell line.
Examination of the VIR data also revealed 184 eGenes interacting with eSNPs ( Figure 2G ). To assess specificity of eQTL localization to interacting regions, we maintained the interaction network by assigning baits to randomly selected promoters and compared the number of interactions supported by eQTL-target gene pairs. We found that eQTLs were significantly more likely to loop to their associated gene than expected by chance, across a broad range of linear distances from their target promoters ( Figure 2G ). Finally, we integrated the PIRs with CCVs 5 and found that CCVs stratified for their association with ER+ and/or ER-tumor subtypes were enriched at PIRs in the ER+ breast cancer cell lines ( Figure 2H) . This enrichment was not as pronounced for the ER-and ERneutral CCVs in the ER-breast cancer and normal breast cell lines, which may indicate a lack of statistical power to detect enrichment or that the underlying mechanisms are more heterogeneous.
Fine-mapping of VCHi-C and PCHi-C profiles
While the CHiCAGO pipeline is extremely useful for interaction detection in CHi-C data 23 , many of the generated contact maps contain contiguous restriction fragments linked with the same target. It is hypothesized that such collateral contacts might result from inaccuracy during the cross-linking process in CHi-C 28 or from bait migration via Brownian motion 29 . Therefore, as a complementary interaction scoring method, we also used a recently developed Bayesian sparse variable selection approach ("Peaky"; 30 ). The model proposes that for any given bait, the expected CHi-C signal at each prey fragment is expressed as a sum of contributions from a set of fragments directly contacting that bait 30 . We applied Peaky to the ~1300 baits from the VCHi-C and ~3200 baits from the PCHi-C (Table S4 ) to derive a measure of confidence in the location of a direct contact called the marginal posterior probability of a contact (MPPC) 30 .
To facilitate a comparison with CHiCAGO-scored interactions, we applied an interaction threshold of MPPC ³ 0.1. We filtered for intrachromosomal and interaction distance £ 2 Mb and detected ~3,500 VCHi-C and ~7,400 PCHi-C interactions per cell type ( Figure S3A and Table S4 ). For the VCHi-C, ~11% of CCV-containing fragments interacted with an annotated protein-or non-coding promoter and for the PCHi-C, ~2.5% of promoter fragments specifically interacted with a CCVcontaining fragment ( Figure S3B and Table S4 ). There were fewer interactions detected by Peaky, perhaps because Peaky can distinguish and rank a subset of direct contacts from long stretches of chromatin interactions 30 . The median linear distance between interactions from either capture was longer than CHiCAGO-scored interactions (ranged from 294-489 kb; Figure S3C ). Similar to CHiCAGO-scored interactions, hierarchical clustering based on MPPC scores also separated the cell lines based on ER status ( Figure S3D) . We then compared the CHiCAGO and MPPC scores for each bait-prey pair. As reported by Eijsbouts et al 30 , we noted that CHiCAGO and MPPC scores were positively correlated ( Figure S3E ; Spearman's r = 0.22-0.37). Peaky was able to refine the number of CHiCAGO-scored interactions by 12-17% in both captures; however a proportion of interactions were identified by Peaky but not CHiCAGO (Figure S3F ). To provide a more stringent list of CCVs and candidate target genes, we combined inferences from the two approaches.
Prioritizing CCVs by Peaky fine-mapping of the PCHi-C data
At many signals, we noted that CHiCAGO identified long stretches of PIRs, some of which contained CCVs. We therefore used Peaky to fine-map the CHiCAGO identified interactions to identify the likely driver contacts within these stretches. This approach proved particularly useful at 9q33.1,
where CHiCAGO identified 24 PIRs starting at ~340 kb from a PAPPA (Pregnancy-associated plasma protein A) promoter ( Figure 3A) . Peaky fine-mapping using a PAPPA promoter bait indicated this stretch of interactions might be explained by a subset of contacts (MPPC ³ 0.1), which spanned one (rs811688) out of 29 CCVs in MCF7 cells ( Figure 3A) . 3C provided further support that the HindIII fragment containing rs811688 was the most frequently interacting fragment with the PAPPA promoter ( Figure S4A ). PAPPA encodes a secreted zinc metalloproteinase and is an important regulatory component of the insulin-like growth factor system 31 . Recent studies indicate PAPPA is frequently overexpressed in luminal B breast tumors 32 and identify PAPPA as a pregnancydependent oncogene that promotes the formation of pregnancy-associated breast cancer 33 .
Another example is 10q14, where CHiCAGO identified 59 PIRs located ~1 Mb from the GATA3 (GATA binding protein 3) promoter. Interactions between GATA3 and CCVs were restricted to the ER+ (T47D and MCF7) breast cell lines and spanned 49 CCVs (Figure 3B) . Peaky fine-mapping indicated this stretch of interactions might be explained by a subset of four contacts, one of which spanned a region containing CCVs. Two HindIII fragments within the CCV-containing peak surpassed the 0.1 MPPC interaction threshold and contained 11 out of the 49 CCVs ( Figure 3B ).
3C provided further support that the HindIII fragment containing 8 CCVs (FragID: 486687) was the most frequently interacting fragment with the GATA3 promoter ( Figure S4B ). Notably, one CCV (rs12765282) within the 3C-identified peak mapped to a putative regulatory element as defined by H3K27ac marks and TF binding in T47D cells ( Figure 3C ). This CCV is predicted to alter a GATA3binding motif, with the risk allele likely acting to decrease GATA3 binding. ChIPseq data showed that GATA3 and ER bound to the CCV site in T47D cells, which are homozygous for the protective gallele ( Figures 3C and 3D) . GATA3 is important in mediating enhancer accessibility for ER 25 , raising the possibility of a GATA3-mediated regulatory loop underlying risk at this region.
Taken together, at 77 signals where we could detect at least one promoter-CCV interaction, we could prioritize 839 out of 4208 CCVs using the combined CHICAGO (score ³ 5) and Peaky (MPPC ³ 0.1) fine-mapping approach. This included 33 signals where the number of prioritized genetically indistinguishable CCVs could potentially be reduced to less than five at each signal (Table S5 ). ChIP-seq data from T47D cells for H3K27ac, GATA3 and estrogen receptor (ER; cells treated with DMSO or 17 beta-estradiol (EST)). The dashed gray outline highlights CCV rs12765282. (d) Position weight matrix of the GATA3 binding site from JASPAR (red arrowhead indicates the CCV position in the motif), with homology to the risk (t) and protective (g) alleles of rs12765282 colored below.
Prioritizing target genes by sequential CHiCAGO and Peaky fine-mapping
The combined analyses can be extended to integrate, where possible, the VCHi-C and PCHi-C data.
One example is 1p22.3, where CHiCAGO detected interactions in the VCHi-C data between two independent signals and the LMO4 (LIM-only protein 4) promoter in Hs578T breast cancer cells ( Figure 4A) . Peaky fine-mapping using signal 2 VCHi-C baits then provided further support that LMO4 was the likely target gene ( Figure 4A ). Peaky was also applied to signal 1 VCHi-C baits, but the resulting contact peaks did not reach the 0.1 MPPC interaction threshold ( Figure S4C ). We then interrogated the PCHi-C data using two LMO4 promoter baits in Hs578T cells. CHiCAGO identified 84 PIRs starting at ~612 kb from the LMO4 promoter ( Figure 4A) . Peaky fine-mapping using the same promoter baits indicated this stretch of interactions might be explained by a subset of three direct contacts (MPPC ³0.1). One contact spanned two HindIII fragments within signal 2 and potentially prioritized four out of eight CCVs at this signal ( Figure 4B ). Of these, one CCV (rs3008455) mapped to a putative regulatory element as defined by open chromatin and TF binding in normal breast cells ( Figure 4B ). This CCV is predicted to alter a CTCF-binding motif, with the risk allele promoting increased CTCF binding ( Figure 4C ). LMO4 is a transcriptional modulator that is overexpressed in >50% of breast tumors 34 . Overexpression of LMO4 promotes cell proliferation, invasion and tumor formation and induces mammary hyperplasia in transgenic mice 35 .
A more complex example is 16q24.2, where CHiCAGO detected 62 VIRs spanning a ~320 Kb genomic region derived from nine separate VCHi-C baits (Figure 4D) . Peaky fine-mapping of this VCHi-C data then prioritized FOXC2, FOXC2-AS1, FOXL1 and MTHFSD as the likely target genes in B80T5 normal breast cells ( Figure 4D) . We interrogated the PCHi-C data using the four target gene promoter baits in B80T5 cells. CHiCAGO identified 40 PIRs spanning a ~500 Kb genomic region. Peaky fine-mapping using the same promoter baits indicated this stretch of interactions might 36 . FOXC2 has been implicated in triple-negative breast cancer progression and therapy resistance 37 , while FOXL1 is reported to inhibit breast cancer cell proliferation, invasion, and migration 38 . Little is known about MTHFSD (Methenyltetrahydrofolate synthetase domaincontaining), but a recent report suggests the gene encodes a stress granule-associated RNA-binding protein 39 .
Identification of 651 candidate target genes at 139 breast cancer risk signals
We defined candidate target genes of breast cancer risk signals by CHiCAGO-and/or Peaky-scored CCV-gene promoter interactions in VCHi-C or PCHi-C in at least two cell lines. This combined analysis resulted in 651 candidate target genes at 139 breast cancer risk signals, including 419 protein-coding genes ( Table S5 ). The majority of candidate target genes interacted with one signal, but ~13% interacted with two or more independent signals (Figure S4D) . The 6q25 region is one of the more extreme examples, where five out of six independent signals all loop to and potentially regulate ESR1 (Figure S4E) . More than 80% of signal-target gene interactions skipped at least one annotated gene promoter and ~75% of signals interacted with at least two promoter-containing fragments (Figures S4F). One example that demonstrates both characteristics is 8q24.13, where signal 1 CCVs interact with six candidate target genes (WDYHV1, FBXO32, CTD-2552K11.2, ANXA13, FAM91A1 and TRMT12) including skipping three annotated genes to contact the TRMT12 promoter ( Figure S4G) . Notably, 181 candidate target genes were identified by both CHiCAGO and Peaky (Figure S4H) , which may further prioritize these genes for functional validation. This priority list includes established breast cancer driver genes such as MYC and GATA3 40 , but also includes many genes with no reported role in breast cancer (Table S5) .
CHi-C identifies TBX3 as the target of multiple risk signals
To further illustrate the power of combining genetic fine-mapping, CHi-C and functional studies, we examined in detail the 12q24 susceptibility region. Genetic fine-mapping of 12q24 identified at least four independent signals 2,5 (listed in Table S6 ); signal 1 (seven CCVs), signal 2 (one CCV) and signal 4 (six CCVs) were more strongly associated with ER+ tumors, whereas signal 3 (eight CCVs) was associated with both ER+ and ER-breast cancer ( Table S6 ). The CCVs in all four signals are located in a large intergenic region on 12q24 between TBX3 and MED13L (Figure 5A) . We used ATAC-seq and available ChIP-seq datasets from ENCODE 41 to map CCVs relative to transcriptional regulatory elements. This analyses showed evidence of putative regulatory elements overlapping the CCVs at each signal, indicating that one or more CCVs likely have high regulatory potential S5A and Table S6 ). Notably, we detected interactions between TBX3 and each of the four independent signals in a cell-type specific manner (Figures 5A and S5B) .
Our functional studies focused on the strongest signal 1 CCVs. CRISPRi-silencing of the signal 1 element in ER+ MCF7 cells showed that TBX3, but not TBX5 and MED13L, levels were significantly reduced ( Figure 5B) . Reporter assays then confirmed that the element acts as an enhancer on the TBX3 promoter in the presence of either the risk or protective haplotypes (Figure 5C ). We used available DNase-seq data derived from heterozygous MCF7 cells to show that the risk a-allele of CCV rs1391721 may promote allele-specific open chromatin (Figure 5D ). Electrophoretic mobility shift assays (EMSAs) then assessed TF binding for each of the signal 1 CCVs. Allele-specific binding by nuclear proteins was observed for CCVs rs2464264, rs2454399, rs1391721 and rs1292011 in MCF7 and BT474 extracts (Figures 5E and S6A) . Further EMSAs using competitor DNA against predicted TFs suggested GATA3 bound to the rs1391721 site ( Figure S6B) . Similar to the 10q14 CCV, rs1391721 is also predicted to lie in a GATA3 binding site. Here, the risk a-allele promoted increased GATA3-binding compared to the protective g-allele (Figure 5F) , as evident in GATA3 ChIP-seq data derived from heterozygous MCF7 cells (Figure S6C) . To assess occupancy of GATA3 in vivo, we performed ChIP followed by allele-specific qPCR in MCF7 cells and found that GATA3 was preferentially recruited to the a-allele of rs1391721 (Figures 5G-H) . As further support, we investigated the correlation between GATA3 and TBX3 expression in the TCGA cohort. A stronger correlation was observed between GATA3 and TBX3 expression in normal breast as compared with the breast tumor samples ( Figure S6D) .
TBX3 is a T-Box TF that has been linked to tumorigenesis by impacting senescence and apoptosis as well as promoting proliferation and tumor formation 42 . To determine whether TBX3 can promote a tumorigenic phenotype in breast cells, we stably overexpressed or repressed TBX3 in the human mammary epithelial (HMLE) cell line and the MCF7 breast cancer cell line. HMLEs have been engineered to express hTERT and the SV40 large-T antigen and can grow in soft agar and form tumors in immune-deficient mice only upon introduction of an additional oncogenic insult 43 .
Overexpression of TBX3 in HMLE cells resulted in a significant increase in cell colony growth in soft agar, suggesting that overexpression promotes anchorage-independent growth (Figures 6A and   S6E) , while CRISPR/Cas9-mediated TBX3 silencing showed a reciprocal effect (Figures 6B) . These results are consistent with our in vitro data which indicated breast cancer risk was likely associated with increased TBX3 expression. The HMLE-TBX3 overexpressing cells were also injected into the mammary fat pads of nude mice, but no tumors were observed, suggesting elevated levels of TBX3 alone is not enough to promote tumor development from these cells. In contrast, overexpression of TBX3 in MCF7 cells decreased cell colony growth in soft agar (Figures 6C and S6F) , while depletion of TBX3 by targeting dCas9-KRAB to the TBX3 promoter resulted in a significant increase in growth (Figures 6D and S6G) . To further investigate TBX3 in tumor growth, TBX3-depleted MCF7 cells were injected into the mammary fat pads of nude mice. Compared to control cells, reduced TBX3 levels resulted in a marked increase in tumor growth in vivo (Figures 6E and 6F) , which was reflected in increased tumor weights ( Figure 6G) . As reported previously 44 , these data suggest that TBX3 can be oncogenic or tumor suppressive depending on cellular context.
DISCUSSION
The field of 3D chromatin interaction mapping is rapidly changing how we view the genome and is revealing important insights into disease biology. Interpretation of findings from GWAS has particularly benefited from the influx of chromatin data, allowing more accurate mapping and redefining of candidate causal genes. In this study, we generated high-resolution chromatin maps in human breast cells to delineate gene-regulatory interactions between breast cancer CCVs and target genes. We used two independent algorithms to score chromatin interactions. Peaky assisted identification of the probable direct contacts from long stretches of CHiCAGO-identified interactions.
This proved useful when examining PIRs as we were able to further prioritize the list of CCVs, which will be valuable in future in-depth functional studies. The de-prioritized variants may simply represent those in linkage disequilibrium with the true causal variant(s). Similarly, we observed an overlap between CHiCAGO-and Peaky-detected target genes, but noted that a proportion was detected by only one method. This was not unexpected given the different statistical models, and further studies will be required to establish parameters for improved resolution of direct interactions. Collectively, we could identify 651 candidate target genes at 139 independent breast cancer risk signals. Of particular interest for post-GWAS functional studies, 65 signals could be prioritized to one or two candidate target genes ( Table 1 ). Some of the listed genes have functional data linking breast cancer CCVs to altered target gene expression, including ESR1 45 , FGFR2 46 and IGFBP5 47 , but most are still uncharacterized.
A recent study used CHi-C to identify 110 putative target genes at 33 breast cancer risk loci 48 . We acknowledge that some CCV-target gene interactions may have been missed due to intrinsic biases in the capture. False negatives may result from lack of suitable baits for some CCV-and promoter-containing fragments, short range contact constraints or due to the transient and cell typespecific nature of regulatory chromatin interactions. It is also important to keep in mind that interactions between a CCV and gene promoter do not infer causality. It is likely that correlated CCVs within some signals have no effect on TF binding or enhancer activity, or they may act via alternate mechanisms. Consistent with other GWAS follow-up studies 49 , our results support the hypothesis that cis-acting regulatory variation is a predominant molecular mechanism at breast cancer risk signals. However, we saw no CCV-target gene looping interactions at 57 (out of 196) risk signals.
Twelve signals contained promoter or coding CCVs, suggesting that direct gene alteration is a probable mechanism underlying these risk associations. The remaining signals (n=45) contained baited variant or promoter fragments, but the lack of detected CCV-gene interactions suggests mechanisms other than distal regulation. A recent study has incorporated some of the proposed alternate CCV mechanisms together with the distally-regulated genes from this study to generate a complete catalog of candidate target genes and biological pathways 5 .
We provided functional evidence that breast cancer risk at 12q24 is driven by the TF, TBX3. TBX3 is overexpressed in many cancers including breast cancer, and contributes to oncogenesis at multiple levels including promotion of proliferation, tumor formation and metastasis 42 . Consistent with previous findings, our in vitro data indicate that the signal 1 CCVs likely act to increase TBX3 expression through recruitment of GATA3 to the CCV site, resulting in increased looping of the risk CCV-containing enhancer to the TBX3 promoter. Several studies have suggested that TBX3 may also function as a tumor suppressor depending on the cellular context 44 . Indeed, in MCF7 breast cancer cells, we showed that TBX3 repression promoted colony formation and in vivo tumor formation. Furthermore, somatic TBX3 mutations in primary breast tumors are predominantly lossof-function through impaired transcriptional repression 50 . Interestingly, a recent report showed that many of these "double agent" genes are TFs and that breast cancer is the second most common cancer type associated with dual-function genes 51 . The molecular mechanisms underlying this duality are largely unknown, but differing mutation spectrums, interaction partners and cellular contexts have been implicated. Dual-function genes likely contribute to the heterogeneity of cancer cells and some are already considered promising targets for breast cancer therapy. It will therefore be important to refine therapeutic strategies to selectively block one function without compromising the other.
In summary, we report the most comprehensive study linking regulatory CCVs to candidate breast cancer genes. This forms an important resource for the breast cancer research community that will facilitate generation of hypotheses, functional experimentation as well as insights into breast cancer biology. We anticipate that many of the candidate target genes may represent drug repositioning opportunities or be suitable for future drug targeting.
METHODS
Data availability
Raw sequencing data has been deposited at EBI: PRJEB29716. Processed Capture Hi-C data is available from https://osf.io/2cnw7/. Processed chromatin interaction data can be visualized at the Washington Epigenome Browser via https://bit.ly/2rnCqS8.
Code availability
The custom scripts used during the study are available from the corresponding author on reasonable request. 
URLs
Hi-C library preparation
Hi-C libraries were prepared from 4-8x10 7 cells per library (two biological replicates per cell line;
three replicates for the T47D VCHi-C) as described previously 11 , but using in-nucleus ligation as described in 52 
Biotinylated RNA bait library design
The SureSelect XT Custom Target Enrichment Arrays were designed using the eARRAY software (Agilent Technologies). For the VCHi-C, biotinylated 120-mer RNA baits were designed to both ends of HindIII restriction fragments that contained at least one CCV 5 . A total of 1448 HindIII fragments were captured, covering 6044/7394 CCVs. For the PCHi-C, biotinylated 120-mer RNA baits were designed to both ends of HindIII restriction fragments that overlapped annotated promoters within 1
Mb of CCVs 5 . A total of 4049 HindIII fragments were captured, overlapping 2298 Ensembl-annotated promoters (GRCh38) 16 . A bait sequence was accepted if its GC content was between 25-65%, the sequence contained no more than two consecutive nucleotides of the same identity, and was within 330 bp of the HindIII restriction fragment end. Repetitive elements were masked using SureDesign masking tools with the highest level of stringency.
Sequencing of CHi-C libraries
PCHi-C and VCHi-C libraries were sequenced on the Illumina HiSeq 2500 platform (Kinghorn Centre for Clinical Genomics, Australia). Two PCHi-C or three VCHi-C libraries were multiplexed per sequencing lane.
PCHi-C and VCHi-C sequence alignment and data processing
Raw sequencing reads were truncated, mapped to the hg19 reference genome, and filtered using the HiCUP pipeline 53 . Individual library statistics are presented in Table S1 . Significant interactions were identified using the CHiCAGO pipeline 23 . For both captures, replicate libraries for each cell line were analyzed separately to learn weights which were then used to merge replicates into a single dataset per cell type. Interactions with CHICAGO scores ≥ 5 in at least one cell type were considered high-confidence interactions.
Principal component and cluster analyses
Principal Component Analysis (PCA) of the CHiCAGO interaction scores was performed for both variant and promoter capture arrays for each individual biological replicate. Interaction length <2 Mb and CHiCAGO score >0 were included. PCA was performed using the R utility prcomp with unit variance scaling. Hierarchical clustering with average linkage based on Euclidian distances was performed on the 1000 interactions with most variance using R's heatmap.2 function. Cell types were clustered based on profiles including interactions with CHiCAGO score >=5 and length <2 Mb.
Interactions with score >=5 in at least one cell line were considered.
PCHi-C and VCHi-C concordance
To examine the overall concordance between promoter and variant captures, we identified interactions common to both experiments from the full range of CHiCAGO scores (>0) for each cell type. The Pearson correlation between CHiCAGO scores for interactions from each of the captures was computed. Interactions scores for each capture were plotted after inverse hyperbolic sine (asinh) transformation with loess smoothed regression lines.
Enrichment of genomic features within interacting regions
Positions of genomic features including DNase-seq peak, histone modification ChIP-seq peaks, transcription factor ChIP-seq peaks (web links provided in Table S7 ) and ATAC-seq peaks were intersected with PIRs from each cell line. Enrichment was estimated by comparing to a set of background PIRs generated by maintaining the distribution of interaction distances and interaction counts relative to promoter baits for each cell type. Interactions were grouped in 50 kb distance bins, and 100 sets of random PIR sets were built for each cell line. We removed baited fragments from the pool of possible PIRs. Z scores were calculated for each genomic annotation.
Fine-mapping of chromatin contacts
PCHi-C and VCHi-C contact mapping was performed using the Peaky Bioconductor package 30 . We first pooled aligned reads from replicate CHi-C libraries. Probable interaction-driving contacts were then modelled for each bait from each cell line independently. We maintained the default W value (5) for each bait. Two parallel chains were run and correlation between MPPC values for interacting prey fragments were tested until r > 0.75 (typically after 20 6 iterations). We achieved successful convergence for >93% tested baits. Distributions derived from parallel chains were then merged to generate cell-type and bait-specific contact maps. An arbitrary MPPC threshold of 0.1 was used for downstream analysis.
Expression quantitative trait loci analysis
To determine whether eSNP-target gene pairs were over-represented within captured interactions, we assigned interactions to random promoters within the same chromosome. This randomization procedure was repeated 10,000 times. The frequency of eSNP-gene occurrences within interactions was then tallied in the observed interaction set and compared to random expectation.
ATAC-seq library preparation and data analysis
ATAC-seq was performed as previously described 54 . Briefly, 5x10 4 Qprofiler assessed the sequence quality and provide fragment length distribution. Peaks were called for each sample using MACS2 58 . Peak annotation was performed using HOMER 59 .
3C validation
3C libraries were generated using HindIII as described previously 47 . 3C interactions were quantified by real-time PCR (qPCR) using primers designed within restriction fragments (Table S6) Data were normalized to the signal from the BAC clone library and, between cell lines, by reference to a region within GAPDH.
CRISPR/Cas9 interference and cutting
For CRISPR interference (CRISPRi), the sgRNA targets (listed in Table S6) For CRISPR cutting (CRISPRc), the GFP control and sgRNA targets (listed in Table S6 ) were synthesized (IDT) and cloned into the pXPR_011 lentiviral vector. Virus-like particles (VLPs) containing the GFP control or targeting sgRNAs were generated by transfection of HEK293 cells with FuGene (Promega). VLPs were collected from culture supernatant, transduced into HMLE-Cas9 cells, and selected using puromycin for at least 48 h.
Quantitative real-time PCR (qPCR)
Complementary DNA (cDNA) was synthesized from RNA samples using SuperScript III (Invitrogen).
qPCR was performed using TaqMan assays (Thermo Fisher Scientific; listed in Table S6 ).
Plasmid construction and reporter assays
The TBX3 promoter-driven luciferase construct was generated by insertion of a PCR amplified promoter fragment into the NheI and HindIII sites of the pGL3-basic vector (primers are listed in Table S6 ). The 12q24 signal 1 enhancer, containing either the risk or protective CCV alleles, was synthesized as gBlocks (IDT) and cloned into the BamHI and SalI sites of the TBX3-promoter construct (coordinates are listed in Table S6 ). Sanger sequencing of all constructs confirmed variant incorporation. MCF7 cells were transfected with equimolar amounts of luciferase reporter plasmids and pRL-TK transfection control plasmid with Lipofectamine 3000 (Thermo Fisher Scientific).
Luciferase activity was measured 24 h post-transfection by the Dual-Glo Luciferase Assay System (Promega). To correct for any differences in transfection efficiency or cell lysate preparation, Firefly luciferase activity was normalized to Renilla luciferase activity, and the activity of each construct was expressed relative to the reference promoter constructs, which were defined to have an activity of 1.
Electromobility shift assays (EMSAs)
Gel shift assays were performed with MCF7 or BT474 nuclear lysates and biotinylated oligonucleotide duplexes (listed in 
TBX3 overexpression
The TBX3 overexpression construct (pLX307/TBX3) was generated by Gateway cloning from pDONR201 containing the full length TBX3 cDNA into the pLEX_307 lentiviral destination vector (Thermo Fisher Scientific). A negative control construct (pLX307/CON) was generated by excising TBX3 via NheI and SpeI restriction enzyme digestion and self-ligating the vector backbone. VLPs were generated from HEK293 cells transfected with pLX307/CON or pLX307/TBX3 as described above and transduced into HMLE or MCF7 cells. Transductants were selected with puromycin for at least 48 h.
Western blotting
Cell pellets were lysed in RIPA buffer ( (vol/vol) Tween 20, PBS). TBX3 was detected with 1 µg/ml rabbit anti-TBX3 antibody (Thermo Fisher Scientific) and actin with 400 ng/ml of rabbit anti-actin antibody (Sigma-Aldrich). Primary antibodies were detected with horseradish peroxidase-conjugated goat anti-rabbit IgG (Cell Signaling).
Detected proteins were visualized with enhanced chemiluminescence substrate (Bio-Rad) and the G:BOX Chemi XX6 gel documentation system (Syngene).
Soft agar colony formation assay
Six-well plates were layered with 0.6% (wt/vol) noble agar (Becton-Dickinson) in RPMI or DMEM medium supplemented with 10% (vol/vol) FBS and antibiotics and allowed to set at 4°C. Twentyfour hours later, cells were trypsinized and 8x10 3 MCF7 or 5x10 4 
Cell proliferation assay
Cell proliferation was measured using a label-free, non-invasive cellular confluence assay on the IncuCyte Live-Cell Imaging System (Essen Bioscience). MCF7 cells were seeded at 20,000 cells/well into 24-well plates and imaged on the IncuCyte using a 10x objective lens every 3 h over 7 days. Imaging was performed in an incubator maintained at 37°C under a 5% CO2 atmosphere.
Cell confluence in each well was measured using IncuCyte ZOOM 2016A software, and the data analyzed using GraphPad Prism. 
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